Moody's Corporation (MCO) Stock Price Today
Aura AI Summary
Key Stats
- $82.64BMarket Cap
- -Volume
- FinancialsSector
- $539.6152W High
- $412.2352W Low
- -Typical Hold Time
- $88.66BEnterprise Value
- 0.86%Div Yield
- -Trading Activity
Track Moody's Corporation (MCO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Moody's Corporation has traded between a low of $412.23 and a high of $539.61, highlighting its annual price range. Buy and sell Moody's Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Most Recent News
CoreWeave draws opposing bets from top investors Tepper and Soros amid AI cloud growth and debt concerns
In Q2 2026, David Tepper's Appaloosa fund initiated a significant new position in CoreWeave, an AI cloud infrastructure company, while George Soros's fund held puts against the same stock but reduced their bearish exposure during the quarter. CoreWea...

Nuclear stocks drop as AI revenue doubts and rising long-term rates hit valuations
Nuclear energy stocks like Oklo, Constellation Energy, and NuScale Power fell sharply due to concerns over AI-related capital expenditure and a spike in long-term Treasury yields to a 19-year high. AI companies reported lower-than-expected revenue fo...

Palvella advances QTORIN for skin disorders with positive Phase 3 data and $230M funding boost
Palvella is progressing its drug QTORIN, targeting microcystic lymphatic malformations and other skin diseases, supported by positive Phase 3 SELVA trial results. The company is leveraging a repeatable regulatory and commercial platform to expand QTO...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.